Venn Life Sciences Holdings PLC Directorate Change (8451M)

TIDMVENN

RNS Number : 8451M

Venn Life Sciences Holdings PLC

12 May 2015

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

Appointment of Chief Financial Officer

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Jonathan Hartshorn as Chief Financial Officer with effect from 15(th) June 2015.

Jonathan is a Chartered Accountant with over 18 years' experience in financial management roles, both as a consultant and as Head of Finance, across a range of industries including a number of large global pharmaceutical businesses.

In 2006, Jonathan became Financial Director of Pfizer Consumer Healthcare Ireland and managed the financial integration of the business with McNeil Healthcare, which created the largest consumer healthcare business in Ireland. In 2008, he left Pfizer to co-found Cara Healthcare Limited, a consumer healthcare training and product development business based in Dublin, before becoming Head of Finance for the onshore division of Mainstream Renewable Power in 2011, from where he joins Venn.

Jonathan qualified from Coopers & Lybrand in Birmingham in 1996 and worked for seven years as a Senior Pharmaceutical Consultant within the Financial Management Group of PricewaterhouseCoopers (later IBM Business Consulting Services) working with companies such as GlaxoSmithKline, AstraZeneca and Novartis.

Tony Richardson, Chief Executive Officer of Venn said: "I am delighted to welcome Jonathan to the Board of Venn as our Chief Financial Officer. As we continue to expand our Pan-European footprint and attract more and more sizeable contracts it is important that we maintain a strong focus on the business's financial management and I am confident that Jonathan will be a great asset to the business in this regard."

Disclosures:

Jonathan David Hartshorn, aged 44,currently holds 44,685 ordinary shares in the Company amounting to 0.11% of the issued share capital of the Company.

Previous Directorships / Partnerships (held in the past five years)

Cara Healthcare Limited

There are no other disclosures required in relation to paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Enquiries:

 
Venn Life Sciences Holdings       www.vennlifesciences.com 
 Plc 
Tony Richardson, Chief Executive      Tel: +353 154 99 341 
 Officer 
Orla Mc Guinness, Marketing          Tel: +33 676 93 11 78 
 Manager 
Zeus Capital (Nominated Adviser 
 and Broker) 
Ross Andrews/Andrew Jones               Tel: 0161 831 1512 
Alex Davies                             Tel: 020 7533 7727 
 
Walbrook PR Ltd                   Tel: +44 (0)20 7933 8780 
                                    or venn@walbrookpr.com 
Paul McManus                      Mob: +44 (0)7980 541 893 
Lianne Cawthorne                  Mob: +44 (0)7584 391 303

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOABCGDUUBBBGUB

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024